Petvivo Holdings Stock Price, News & Analysis

PetVivo Holdings (OTCQX: PETV; OTCID PETVW) announced that Josh Ruben has joined its Board of Directors effective Oct. 28, 2025. Ruben is Managing Director of Life Sciences at Trinity Capital and previously spent 12 years in investment banking, most recently as Head of Life Science Tools and Diagnostics coverage at RBC Capital Markets.

The company highlighted Ruben’s experience in healthcare finance, venture lending, and executing multi‑billion‑dollar M&A and capital transactions as qualifications to support PetVivo’s veterinary Spryng® product and potential expansion into human therapeutics.

PetVivo Holdings (OTCQX: PETV) entered an exclusive 10-year white-label B2B licensing agreement with Digital Landia for Agentic Pet AI, a two-sided platform linking Gen Z pet parents to veterinary clinics. The deal includes 1 million restricted shares and covers 5 patent-pending innovations and 9 AI diagnostic agents. PetVivo cites a Q1 FY2026 revenue growth of 141% YoY and record fiscal 2025 revenue of $1.13 million. The companies plan a dual-platform launch in Q1 2026 targeting a $4.9 billion US veterinary AI market and 30,000+ clinics, claiming potential client acquisition costs of $1.50–$5.00.

PetVivo (OTCQX: PETV) announced a Vendor Partner Agreement with Veterinary Growth Partners (VGP) on October 16, 2025 to expand commercial access to its veterinary therapeutics.

Under the agreement VGP — which serves over 7,300 veterinary members — will promote PetVivo’s flagship products Spryng with OsteoCushion Technology and PrecisePRP across its network, streamlining purchasing and access for member practices. PrecisePRP is an off-the-shelf, leucoreduced allogeneic PRP product with 4 billion platelets per vial (500,000 platelets/μL) and <1500 WBC/μL. The agreement aims to accelerate national availability and product adoption for non-pharmaceutical regenerative treatments.

PetVivo Holdings (OTCQX: PETV) has successfully executed note conversion agreements with four existing shareholders, converting $2,018,155 of outstanding debt into 3,669,806 shares of common stock. The debt consisted of $1,850,000 in principal plus $168,155 in accrued interest, with conversion prices ranging from $0.50 to $0.75 per share.

The converted debt proceeds were used to commercialize the company's flagship products: SPRYNG® with OsteoCushion® Technology, an injectable veterinary device for joint pain management, and PrecisePRP®, an off-the-shelf platelet-rich plasma product for veterinary use. This debt elimination strengthens PetVivo's balance sheet and enables greater focus on strategic growth initiatives.

PetVivo Animal Health (OTCQX: PETV) has launched three new RACE-approved continuing education (CE) courses for veterinary professionals, each offering 1.0 credit hour. The courses focus on osteoarthritis (OA) management and regenerative therapies for both small animal and equine practices.

The educational program includes three distinct courses: an introductory course on OA care in small animals, an advanced course on joint injections, and a specialized course on regenerative therapies in equine practice. These courses combine scientific research with practical instruction and are available at no cost to veterinary professionals through PetVivo's online learning platform.

PetVivo Holdings (OTCQX: PETV) has entered into a distribution agreement with Nupsala Limited to market and distribute Spryng® with OsteoCushion® technology throughout the United Kingdom, effective September 1, 2025.

Spryng® is an intra-articular injectable veterinary medical device containing sterilized, extra-cellular matrix microparticles that integrate with the animal's subsynovial tissue. The technology aims to restore proper joint mechanics and manage conditions like joint instability, degenerative joint disease, and osteoarthritis in horses, dogs, and cats.

PetVivo Holdings (OTCQX: PETV) reported strong fiscal Q1 2026 results with revenue increasing 141% to $298,000, driven by product line expansion and distributor network growth. The company's national distributor sales surged 192% to $198,000, representing 67% of total revenues.

Key operational highlights include signing a distribution agreement with Eq Especialidades for Mexico market entry, partnerships with PiezoBioMembrane for biomaterial development, and Digital Landia for AI integration. The company also secured a $4.4 million private placement and uplisted to the OTCQX Best Market.

Financial metrics show a gross profit increase of 69% to $187,000, though operating loss improved 9% to $1.8 million. Cash position strengthened to $3.3 million, up from $228,000 in March 2025, while total liabilities decreased 39% to $3.1 million.

PetVivo Holdings (OTCQX: PETV), a biomedical company focused on innovative medical devices and therapeutics for equines and companion animals, has scheduled its fiscal first quarter 2026 earnings conference call for Thursday, August 14, 2025, at 5:00 p.m. ET.

The company will release its financial results for the quarter ended June 30, 2025, prior to the call. Management will host a presentation followed by a Q&A session. Investors can access the call via toll-free dial-in or webcast, with replay options available through the company's investor relations website.

PetVivo Holdings (OTCQX: PETV) has announced its upgrade from the OTCQB Venture Market to the OTCQX Best Market, marking a significant milestone for the biomedical device company. The OTCQX Market, which currently hosts 625 securities out of approximately 12,000 OTC securities, is designed for established companies meeting high financial standards and corporate governance requirements.

The company specializes in innovative medical devices for horses and companion animals, featuring two key products: Spryng with OsteoCushion Technology, an intra-articular injectable device for joint pain management, and PrecisePRP, an off-the-shelf platelet-rich plasma product containing 4 billion platelets per vial for veterinary use.